All In Biotech

NDA 021163 · Sandoz Canada INC

Infuvite Adult

Alpha-Tocopherol Acetate, Ascorbic Acid, Biotin, Cholecalciferol, Cyanocobalamin, Dexpanthenol, Folic Acid, Niacinamide, Pyridoxine Hydrochloride, Riboflavin 5'-Phosphate Sodium, Thiamine Hydrochloride, Vitamin A Palmitate, Vitamin K · Intravenous

Last checked: Nov 20, 2026Latest source record: Nov 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

May 18, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

143

39 Phase 3, 8 recruiting

FAERS reports

141

51 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 6, 2024.

INFUVITE ADULT is a combination of vitamins indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. INFUVITE ADULT is a combination of vitamins indicated for prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 18, 2000 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
2 products under this application
  • INFUVITE ADULT · ALPHA-TOCOPHEROL ACETATE 2 IU/ML; ASCORBIC ACID 40MG/ML; BIOTIN 12MCG/ML; CHOLECALCIFEROL 40 IU/ML; CYANOCOBALAMIN 1MCG/ML; DEXPANTHENOL 3MG/ML; FOLIC ACID 120MCG/ML; NIACINAMIDE 8MG/ML; PYRIDOXINE HYDROCHLORIDE 1.2MG/ML; RIBOFLAVIN 5'-PHOSPHATE SODIUM 0.72MG/ML; THIAMINE HYDROCHLORIDE 1.2MG/ML; VITAMIN A PALMITATE 660 IU/ML; VITAMIN K 30MCG/ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • INFUVITE ADULT · ALPHA-TOCOPHEROL ACETATE 2 IU/ML; ASCORBIC ACID 40MG/ML; BIOTIN 12MCG/ML; CHOLECALCIFEROL 40 IU/ML; CYANOCOBALAMIN 1MCG/ML; DEXPANTHENOL 3MG/ML; FOLIC ACID 120MCG/ML; NIACINAMIDE 8MG/ML; PYRIDOXINE HYDROCHLORIDE 1.2MG/ML; RIBOFLAVIN 5'-PHOSPHATE SODIUM 0.72MG/ML; THIAMINE HYDROCHLORIDE 1.2MG/ML; VITAMIN A PALMITATE 660 IU/ML; VITAMIN K 0.03MG/ML · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Alpha-Tocopherol" as an intervention, any sponsor and status, largest first.

All 143 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • flushing32
  • dyspnoea31
  • chest discomfort25
  • infusion related reaction18
  • nausea15
  • vomiting14
  • dizziness13
  • maternal exposure during pregnancy12
  • hypersensitivity10
  • anaphylactic reaction9
  • chest pain8
  • feeling abnormal8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20052
20081
20092
20102
20112
20124
20132
20142
20151
20161
20173
20187
201913
202010
202114
202220
202318
202412
202510
202614

Recalls

1 FDA enforcement reports for this application.

  • Apr 25, 2025 · Class II · Ongoing

    Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected...

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,359 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.